ArticleHeliyon2024
Changes in threats from chronic obstructive pulmonary disorder and lung cancer with environmental improvements in China: Quantitative evaluation and prediction based on a model with age as a probe.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Various indicators can be used to assess threats from chronic diseases. This study presented new indicators of quantitative evaluation and prediction of threats from chronic obstructive pulmonary disorder (COPD) and lung cancer and assessed relevant changes in these indicators occurring with environmental improvements. Age at zero mortality (AM0) and age at average mortality (AMa) values were calculated based on the regression of the linear relationship of age with mortality for COPD or lung cancer. The lower the AM0 or AMa of a chronic disease, the greater the threats from the disease to a population were considered to be. AM0 values of both diseases were higher in 2019 than in 2004. Moreover, AM0 was lower for lung cancer than for COPD (0.365 vs. 41.643); however, lung cancer and COPD demonstrated almost identical values for age-standardized mortality. AMa values of both the diseases in 2004 and 2019 were within the range of the median age group (70-74 years). In recent years, the overall mortality risk for lung cancer and COPD has decreased with environmental improvement, and aging has played a major role in lung cancer and COPD development. AM0 and AMa values may be used as a theoretical basis for further research on chronic diseases, particularly lung cancer and COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.